Metformin rescues Parkinson's disease phenotypes caused by hyperactive mitochondria

Area of Science:

• Neuroscience
• Metabolic research
• Aging

Background:

• Metabolic dysfunction is common in age-related neurodegenerative diseases, but its role is unclear.
• A link between branched-chain amino acid transferase 1 (BCAT-1) and Parkinson's disease (PD) has been proposed.
• BCAT-1 knockdown in model organisms causes PD-like symptoms, but mechanisms are unknown.

Purpose of the Study:

• To investigate the mechanisms by which BCAT-1 influences neurodegeneration in PD.
• To explore the role of mitochondrial function in BCAT-1-associated neurotoxicity.
• To evaluate metformin as a potential therapeutic agent for PD.

Main Methods:

• Transcriptomic, metabolomic, and imaging analyses were employed.
• RNA interference (RNAi) was used to knockdown BCAT-1 in model systems.
• Metformin was administered post-disease onset to assess its therapeutic effects.

Main Results:

• BCAT-1 knockdown led to increased mitochondrial respiration and oxidative damage in neurons via mTOR-independent pathways.
• This mitochondrial hyperactivity was essential for BCAT-1 knockdown-induced neurotoxicity.
• Metformin treatment reversed mitochondrial hyperactivity and significantly improved motor deficits and neuronal survival.

Conclusions:

• Mitochondrial hyperactivity may be an early pathogenic event in Parkinson's disease.
• Targeting mitochondrial respiration presents a novel therapeutic strategy for PD.
• Metformin shows potential for treating PD by modulating mitochondrial function.